Mounjaro UK The Complete Plain English Guide

What is Mounjaro?

Mounjaro is a weekly weight loss injection available in the UK. Its active ingredient is tirzepatide, pronounced teer-ZEP-ah-tide. It was developed by Eli Lilly, the same pharmaceutical company that is developing retatrutide, the next-generation weight loss treatment currently awaiting regulatory approval.
Mounjaro is licensed in the UK by the MHRA, the Medicines and Healthcare products Regulatory Agency, for chronic weight management in adults who meet specific criteria. It is also licensed for type 2 diabetes management, though it is increasingly used primarily for weight loss.
It is a once-weekly injection administered using a small pre-filled pen. Most people inject into the stomach, thigh or upper arm. The injection itself takes seconds and most people describe it as virtually painless.

How does tirzepatide work?

Your gut produces hormones every time you eat. Two of the most important for appetite control are GLP-1 and GIP. GLP-1 tells your brain you are full and slows down how quickly your stomach empties. GIP works alongside it to regulate blood sugar and appetite through a slightly different pathway.
Tirzepatide mimics both hormones simultaneously. According to Eli Lilly, it is what researchers call a dual agonist, meaning it activates two hormone receptors at once rather than just one.
The practical effect is a significant and sustained reduction in appetite. Most people find they feel full much faster than before, their interest in food reduces noticeably, and cravings, particularly for high-calorie food, diminish considerably. This is not willpower. It is a measurable biological change in how the brain and gut communicate about hunger.
For comparison, Ozempic and Wegovy contain semaglutide, which targets only the GLP-1 receptor. Mounjaro’s dual action on both GLP-1 and GIP is the primary reason it consistently produces greater average weight loss than semaglutide-based treatments in head-to-head comparisons.

Mounjaro vs Ozempic vs Wegovy – the honest comparison

Ozempic contains semaglutide at doses up to 1mg. According to the MHRA, it is licensed in the UK for type 2 diabetes only, not for weight loss. Some doctors prescribe it off-label for weight management, but this is technically outside its licensed indication. In clinical trials, Ozempic produced average weight loss of around 12 to 15 percent of body weight.
Wegovy also contains semaglutide but at higher doses, 2.4mg and, since January 2026, 7.2mg. According to the MHRA, Wegovy is specifically licensed for weight management in the UK. The standard 2.4mg dose produced average weight loss of around 15 percent in clinical trials. The new 7.2mg dose, approved by the MHRA in January 2026, produced average weight loss of around 20.7 percent according to the STEP UP trial.
Mounjaro at its highest dose of 15mg produced average weight loss of around 20 to 22 percent in the SURPASS-CVOT and SURMOUNT trials. According to NICE, around 10 to 15 percent of Mounjaro trial participants lost 30 percent or more of their body weight, a result previously associated only with bariatric surgery.
The honest summary: Mounjaro and high-dose Wegovy now produce comparable average results. Mounjaro has the longer track record and more extensive real-world data in the UK. For most patients, both are legitimate options and the choice often comes down to availability, cost and individual tolerance. For the fuller picture, including quality of life, dropout rates and long-term outcomes, see our weight loss jabs and pills compared guide, based on a major 2026 BMJ analysis.

What did the SURPASS trials actually show?

The SURMOUNT programme was the series of Phase 3 clinical trials that established Mounjaro’s effectiveness for weight management. The most relevant for UK patients is SURMOUNT-1, published in the New England Journal of Medicine in 2022.
According to the New England Journal of Medicine, SURMOUNT-1 involved 2,539 adults with obesity or overweight with at least one weight-related condition. Participants received tirzepatide at 5mg, 10mg or 15mg weekly, or a placebo, over 72 weeks.
The results were significant. According to the New England Journal of Medicine, participants on the 15mg dose lost an average of 22.5 percent of their body weight. Those on 10mg lost an average of 21.4 percent. Even the lowest 5mg dose produced average weight loss of 16 percent.
To put that in plain terms. Someone starting at 14 stone on the highest dose would lose an average of just over three stone. Someone starting at 16 stone would lose closer to three and a half stone on average.
The trial also showed that 57 percent of participants on the highest dose lost 20 percent or more of their body weight, and around 15 percent lost 30 percent or more, the threshold associated with bariatric surgery outcomes.
These are trial results under controlled conditions. Real-world outcomes vary. Most UK patients and clinicians report that Mounjaro delivers meaningful weight loss in everyday clinical practice, though results vary between individuals depending on starting weight, diet, activity and other factors.

Side effects – the full honest picture

Mounjaro’s side effects are real and worth understanding before you start. The most commonly reported are gastrointestinal, meaning they affect the stomach and digestive system.
According to the MHRA, the most frequently reported side effects include nausea, vomiting, diarrhoea, constipation, and stomach pain. These are most common in the early weeks of treatment and after each dose increase. For most people they are manageable and improve as the body adjusts.
Practical tips that help: inject in the evening so any nausea occurs overnight. Eat smaller portions. Avoid rich, greasy or spicy food particularly in the first few weeks. Eat slowly and stop as soon as you feel full, ignoring that signal causes discomfort.
A minority of people, around 5 to 8 percent in trials, stop treatment because of side effects they cannot tolerate. If that happens, it does not mean no treatment is right for you. Wegovy uses a different drug and some people tolerate one better than the other.
More serious but rarer side effects include pancreatitis, severe inflammation of the pancreas. According to the MHRA, safety warnings for all GLP-1 and dual GLP-1/GIP medications were strengthened in January 2026 following post-marketing reports of rare but serious pancreatitis cases, including some fatal cases. Severe abdominal pain that does not pass is a medical emergency. Stop your medication and seek immediate help.
People combining Mounjaro with insulin or sulfonylureas, a class of diabetes tablets, face an increased risk of hypoglycaemia, meaning dangerously low blood sugar. This requires careful monitoring and should be discussed with your prescriber.
One side effect that most clinics do not mention: if Mounjaro causes dizziness or fatigue and you drive, UK law may require you to inform the DVLA. According to the DVLA, failing to declare a medication that impairs your driving can result in a fine of up to £1,000.
Hair thinning is reported by some patients, particularly in the first few months. According to dermatologists, this is typically linked to rapid weight loss rather than the drug itself and usually resolves.

How to get Mounjaro on the NHS

NHS access to Mounjaro has expanded significantly in 2026 but remains subject to eligibility criteria.
According to NHS England, the current phased rollout criteria require a BMI of 40 or above, or 37.5 or above if you’re of South Asian, Chinese, other Asian, Middle Eastern, Black African or Caribbean origin, alongside at least four qualifying weight-related health conditions. These conditions include type 2 diabetes, high blood pressure, cardiovascular disease, sleep apnoea and certain other weight-related health problems. Your GP will assess which conditions count based on current NHS clinical guidance.
From April 2026, tirzepatide prescribing was embedded into the 2026/27 GP contract through new Quality and Outcomes Framework indicators. According to NHS England, this means GPs now have a formal funded mechanism to prescribe Mounjaro directly, rather than requiring patients to wait for a specialist weight management referral, for those who meet the criteria above.
In practice, rollout is uneven. Some GP practices have implemented the new pathway promptly. Others are slower. If you believe you meet the criteria, book an appointment and ask specifically whether you qualify for tirzepatide under the current NHS contract. Go prepared with a list of your qualifying conditions.
If your GP is uncertain or says they cannot prescribe it yet, or if your BMI is below the primary care threshold, you have every right to ask for a referral to a specialist weight management service, which uses broader eligibility criteria. Waiting lists exist in some areas but the referral gets you into the system.
NHS prescriptions are free for patients who qualify. If you are on a prepayment certificate or exempt from prescription charges, check with your GP whether this applies to your Mounjaro prescription.

How to get Mounjaro privately

Private access to Mounjaro is available through a number of regulated UK online clinics and pharmacies. The process typically involves an online medical questionnaire, a consultation with a prescriber, and delivery to your door.
Before using any private provider, check two things. First, confirm they are registered with the Care Quality Commission register. Second, confirm their dispensing pharmacy is registered with the General Pharmaceutical Council register. Both checks are free and take minutes.
A legitimate private provider will always conduct a proper medical assessment before prescribing. They will monitor you throughout treatment with regular check-ins. They will be transparent about the exact drug, dose and dispensing pharmacy they use. They will not offer Mounjaro without a consultation.
Red flags to avoid: no medical questionnaire before purchase, prices dramatically below the market rate, no UK address or contact number, and claims that no prescription is needed.
According to the MHRA, counterfeit and unlicensed versions of tirzepatide are circulating in the UK. An unlicensed product has not been checked for purity, concentration or sterility. The risk of injecting an unverified substance is real.
Reputable providers currently operating in the UK include Juniper, Voy, Numan, Second Nature and heySlim, among others. Our UK Clinic Reviews section covers these in more detail.

What does Mounjaro cost in the UK?

NHS prescriptions are free for qualifying patients.
Privately, costs vary by provider and dose, and change often. See our independent Mounjaro price comparison for live, up to date prices across every major UK clinic rather than relying on a figure here that may be out of date. As a general guide, starter doses typically begin at around £164 to £200 per month with established reputable providers, with higher maintenance doses costing more.
Following Eli Lilly’s September 2025 price increase, costs rose across most UK private providers. Some clinics responded by reducing prices on Wegovy to offer an alternative at a lower price point.
Be very cautious of prices significantly below the going rate shown on the comparison page. Counterfeit products are a real and documented risk in the UK private market.

What happens when you stop Mounjaro?

This is one of the most important questions, and one that is not discussed honestly enough.
According to clinical trial data published in the New England Journal of Medicine, most people regain a significant proportion of the weight they lost within 12 months of stopping tirzepatide. In the SURMOUNT-4 trial extension, participants who stopped treatment after 36 weeks regained on average about two thirds of the weight they had lost by the end of the follow-up period.
This is not a personal failing. It is biology. Tirzepatide changes how the brain and gut communicate about hunger. When the drug stops, those signals return to their previous state. For most people, hunger increases and weight follows.
This does not mean Mounjaro is not worth taking. The health benefits of sustained weight loss, reduced blood pressure, improved blood sugar, better joint health, lower cardiovascular risk, are real and meaningful during the period of treatment. For some people, the lifestyle changes they make during treatment help them maintain some of the loss after stopping.
But anyone considering Mounjaro should understand this reality before starting. It is not a cure. It is a treatment. Like many effective treatments for chronic conditions, it works while you take it.

Maintaining weight loss long term

The evidence on long-term maintenance after stopping GLP-1 and dual GLP-1/GIP treatment is still developing. What is known is that people who make meaningful changes to their eating patterns and activity levels during treatment tend to maintain more of their weight loss after stopping than those who rely on the drug alone.
According to NICE clinical guidance, Mounjaro is most effective when combined with a reduced-calorie diet and increased physical activity. This is not a disclaimer, it is clinically meaningful. The drug reduces hunger significantly, which makes dietary change easier than it would otherwise be. Using that window to build sustainable habits is the most evidence-based approach to long-term maintenance.
Some patients choose to continue treatment indefinitely. According to NHS England, ongoing prescribing decisions should be reviewed regularly with a prescriber and based on continued clinical benefit.
For people considering stopping, a gradual dose reduction rather than abrupt cessation is generally recommended. Discuss any plans to stop or reduce with your prescriber, do not make changes without medical advice.

Frequently Asked Questions

This guide is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.